Introduction
Stat transcription factors were ®rst de®ned in the context of the IFN signaling system from studies characterizing the molecular determinants of signal transduction speci®city. The motivation for these studies derives from evidence that IFNa and IFNg induced rapid but largely distinct changes in gene expression in target cells (Fan et al., 1988 (Fan et al., , 1989 Friedman et al., 1984; Larner et al., 1984; Revel and Chebath, 1986) , re¯ecting their largely distinct biology of inducing direct antiviral action versus modulation of immune cell function, respectively. The discovery of a family of transcription factors that could be activated by a cell surface receptor and deliver information directly to the nucleus to modulate gene expression with the same speci®city inherent in the ligand-receptor interaction, provided an appealing explanation of how speci®city is maintained during signal transduction (Levy and Darnell, 1990) . This initial picture became somewhat clouded by the observation that both IFNa and IFNg acted through signaling pathways that were not only analogous but that used overlapping components, in particular the Stat1 protein (Shuai et al., 1992) . Furthermore, it was found that Stat proteins were activated by a broader array of cytokines and growth factors than just the IFNs, with reports that Stat-like proteins were activated by EGF, PDGF, GH, PRL, FGF, insulin, many interleukins, angiotensin 2, and tyrosine kinase oncoproteins, among others (Darnell, 1997) . These observations led to questions concerning the degree to which Stat proteins explained the speci®city of cytokine signaling.
The seven known mammalian Stat proteins can be classi®ed into two groups, based on their activation pro®les in vitro. Stat1, 3, 5a and 5b are activated by a large number of both extracellular and intracellular stimuli, while Stat2, 4 and 6 are primarily activated by only a single extracellular factor. The association of Stat protein activation with agents that modulate cell growth has suggested a role for these proteins in cellular growth control, and their disregulation in malignant cells points to an important role in cancer (Catlett-Falcone et al., 1999) .
Because the initial observations of Stat protein activation were made using tissue culture model systems, it became important to determine the action of these transcription factors in vivo.
One approach to understanding Stat physiology has been to study the phenotype of null mutations in the mouse. To date, all seven mouse Stat genes have been disrupted in transgenic animals, and mice with homozygous null mutations in more than one Stat gene are beginning to be generated. Most of thesè knockout' animals have been studied in more than one laboratory, and the consensus that is emerging reinforces the notion that Stat proteins lie at the heart of cytokine signaling speci®city. This approach is also elucidating potential roles for Stat proteins in cancer. In this review, we discuss the roles of two Stat proteins, Stat1 and Stat5, in cell growth and malignancy.
Stat1
The ®rst Stat gene to be disrupted in mice was Stat1. Stat1-mutant mice were created that expressed either a truncated and crippled Stat1 protein that displayed no activity (Meraz et al., 1996) or that expressed no detectable Stat1 protein (Durbin et al., 1996) . Results obtained with theses two mutant strains thus far have been entirely consistent, with the major defect associated with the null phenotype being unresponsiveness to both type I and type II IFN. This loss of IFN responsiveness Oncogene (2000) 19, 2505 ± 2510 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: DE Levy would be predicted from the involvement of the Stat1 protein in signaling from both the IFNa and the IFNg receptors Shuai et al., 1992) , and is consistent with ®ndings from mutant tissue culture cell lines (MuÈ ller et al., 1993) . Remarkably, however, these initial studies of Stat1-null mice did not reveal phenotypes consistent with defects in any other cytokine or growth factor signaling pathway. Speci®cally, these animals showed no gross developmental defects as might be predicted from impaired EGF or PDGF signaling (Leveen et al., 1994; Sibilia and Wagner, 1995; Threadgill et al., 1995) , and no impaired responses to signals that had been found to cause Stat1 activation in cell culture models, such as GH, IL10, or CSF-1. These results suggested that Stat1 utilization is remarkably speci®c to the IFN system in vivo. The expanded range of Stat1 activation observed in cell culture systems that is not re¯ected in the null phenotype, could have resulted either from a loss of speci®city inherent in these in vitro systems or from redundancy, due to similar proteins still functional in vivo, perhaps other Stats. Many of the non-IFN activation events involving Stat1 observed in cell culture have not been observed in vivo or in primary cells ex vivo, arguing for the ®rst possibility. However, some non-IFN activators are functional even on primary cells (for example, activated Stat1 has been noted in IL12-treated lymphocytes that might be redundant with activated Stat4), suggesting that animals with compound lesions in multiple Stat genes will be required to de®nitively address this issue. While some of these multiply mutant mouse strains have been produced through interbreeding, others will be more dicult to produce due to the close genetic linkage of Stat gene clusters (Copeland et al., 1995) .
The primary defect in Stat1-mutant mice is susceptibility to microbial infections, similar to the combined phenotypes of IFNAR17/7 or IFNAR27/7 and IFNGR17/7 or IFNGR27/7 mice (Huang et al., 1993; Hwang et al., 1995; MuÈ ller et al., 1994) . For example, Stat17/7 mice were exquisitely susceptible to vesicular stomatitis virus infection which produced lethal disease with extensive virus replication in mutant animals at challenge doses 10 8 -fold lower than in their wild-type counterparts. This enhanced susceptibility re¯ects the primary role of type I IFN-induced cellular antiviral systems in preventing VSV replication in vivo. Likewise, Stat17/7 mice were unable to cope with infections by Listeria monocytogenes or Lieshmania major, re¯ecting the known requirements for IFNg for defense against these pathogens (Buchmeier and Schreiber, 1985; Swihart et al., 1995; Wang et al., 1994) . Molecular markers of IFN action were also aected by mutation of the Stat1 gene. Macrophages were unable to up-regulate nitric oxide production in response to IFNg; splenocytes and ®broblasts failed to show increased IFN-stimulated gene expression in response to either IFNa or IFNg; and ®broblast growth was not arrested by IFN treatment. However, other responses, such as those mediated by NF-kB, were largely intact.
Stat1, growth control, and cancer
IFNs are not just involved in innate immunity but also exhibit potent antiproliferative eects on both normal and malignant cells. This property has led to their use as chemotherapeutic agents, and are particularly successful for the treatment of some forms of leukemia, such as hairy cell, chronic myelogenous, and acute promyelocytic leukemias. Given the requirement of Stat1 for the action of IFN, it was possible that loss of Stat1 would lead to increased incidence of cancer due to failure of negative growth control pathways. Inappropriate activation of Stat1 has also been observed in a variety of malignant cells, such as breast cancer, head and neck neoplasms, melanoma, lymphoma, and leukemias, suggesting that Stat1 may contribute to rather than inhibit malignant transformation. These concepts have been examined in Stat1-de®cient mice.
Stat1-de®cient mice have not been reported to display heightened spontaneous malignancy. However, analysis of chemical carcinogenesis in Stat1-mutant and IFNg receptor-mutant animals revealed the existence of an IFNg-mediated tumor surveillance system that operates in immunocompetent animals (Kaplan et al., 1998) . This study demonstrated that endogenously produced IFNg was required for a tumor surveillance system capable of controlling development of both chemically induced and spontaneously arising tumors. Compared with wild-type mice, animals lacking sensitivity to either IFNg alone or all IFN family members (i.e., Stat1-de®cient mice) developed tumors more rapidly and with greater frequency when challenged with dierent doses of the chemical carcinogen methylcholanthrene. In addition, IFNginsensitive mice developed tumors more rapidly than wild-type mice when bred onto a background de®cient in the p53 tumor-suppressor gene. IFNg-insensitive p537/7 mice also developed a broader spectrum of tumors compared with mice lacking p53 alone. Studies of the growth of tumor cells derived from methylcholanthrene-treated IFNg-insensitive mice demonstrated that this enhanced tumor phenotype was at least partly mediated through indirect eects of IFNg on the tumor cell leading to enhanced tumor cell immunogenicity rather than direct antiproliferative eects on tumor cell growth. Interestingly, certain types of spontaneously arising human tumors were found to be selectively unresponsive to IFNg due to molecular defects in the Stat1-activation pathway, suggesting that a similar tumor surveillance system operates in humans as well. In addition to enhanced growth of IFNg-insensitive tumors, growth of transplanted tumors in Stat1-de®cient or IFNg-insensitive mice demonstrated a defect in host response to tumors that was independent of the genotype of the tumor. Therefore, not only enhanced tumor immunogenicity but also the ability of the host to recognize and/or eliminate tumor cells was diminished in the absence of a functioning IFNg system.
Given the multitude of agents other than IFN capable of activating Stat1 in cell culture models, eorts have been made to ®nd Stat1-dependent phenotypes not readily explained by loss of IFN responsiveness. One such phenotype involves the basal expression of MHC class I antigens on peripheral T lymphocytes. MHC class I expression and many aspects of the class I antigen processing and presentation machinery are induced in response to IFN. However, most non-neuronal nucleated cells also constitutively express basal levels of MHC class I. This basal expression was found to be reduced on cells from Stat17/7 animals, particularly on mature T cells. Comparison of class I levels on lymphocytes from IFN-unresponsive strains due to loss of IFNa receptors, IFNg receptors, or both receptors demonstrated an IFN-dependent component to this response. However, there was a much greater loss of MHC I expression in Stat1-de®cient animals than that observed following loss of IFN-responsiveness alone. This defect in MHC I expression was particularly pronounced on mature T cells where it appeared to re¯ect a requirement for IL-7 and Stat1 in the maintenance of normal cell surface protein expression (Lee et al., 1999) .
MHC class I proteins are involved in antigen presentation during infection, but they also play a role in tumor surveillance by the immune system. Defects in MHC class I protein expression as well as defects in the host response to tumor cells in the absence of Stat1 prompted investigation of tumor rejection in Stat1-de®cient mice. Natural killer (NK) cells are cytotoxic lymphocytes that exhibit cytolytic activity toward tumor cells. While mice de®cient in Stat1 displayed a decreased basal NK cell activity in vitro, the development and number of the NK cell population appeared to be normal. NK cell activity could be enhanced by in vivo treatment with IL-12, but treatment with the NK cell inducer poly(IC) had no eect on Stat17/7 mice. A similar phenotype was found in mice devoid of IFNa receptors, suggesting that induction of NK cells by poly(IC) was completely dependent on type I IFN responsiveness which was lost in the absence of Stat1.
Stat1-de®cient mice were impaired in their ability to reject transplanted tumors, even when those tumors were themselves wild-type for Stat1 and therefore sensitive to the eects of IFN. Despite the response of NK cells to IL-12 in vitro, Stat17/7 mice were unable to mount eective tumor rejection after in vivo administration of IL-12. Interestingly, IL-12-induced IFNg production, which may be important for controlling tumor growth, was also reduced in Stat17/7 mice. These results suggest that Stat1 plays a role in rejection of tumors through a variety of mechanisms, including maintenance of NK cell cytolytic activity, production of and response to IFN, and tumor recognition (unpublished data).
IFN also plays a direct role in growth inhibition, and this growth inhibitory activity is dependent on Stat1-induced gene expression (Bromberg et al., 1996 (Bromberg et al., , 1998 . Therefore, it was of interest to consider the possible role of Stat1 in normal cellular growth control and how its loss might lead to malignancy. Lymphocytes from Stat1-de®cient mice were less susceptible to apoptosis and exhibited increased proliferation in vitro (Lee et al., 2000) . Reduced apoptosis correlated with depressed levels of caspase 1 and 11, though other proapoptotic gene expression appeared normal in contrast to what was observed in cell culture (Kumar et al., 1997) . While increased survival contributed to enhanced growth, loss of Stat1 also had a direct aect on the cell cycle. Stat1-de®cient cells entered S phase more eciently, due at least in part to more rapid destruction of the cyclin-dependent kinase inhibitor p27 kip1 and induction of cyclin A, leading to increased CDK2 catalytic activity. Therefore, the increased incidence of tumors in carcinogen-treated Stat1-de®-cient mice may be due both to impaired immune surveillance (Kaplan et al., 1998) , defects in NK cell activity, and to altered intrinsic growth regulation (Lee et al., 2000) .
Another example of the loss of growth inhibition following disruption of Stat1 has been observed in the ®broblast growth factor (FGF) system. It has been suggested that hyperactivation of Stat1 might be involved in the growth impairment observed in genetic forms of dwar®sm involving activated mutations in FGF receptor (Su et al., 1997) . Primary chondrocytes derived from Stat1-de®cient embryos were found to be defective in FGF-mediated growth inhibition, even though normal levels of FGF receptors were expressed (Sahni et al., 1999) . Furthermore, organ cultures of bone rudiments from mouse embryos showed that FGF treatment produces a drastic impairment of chrondrocyte proliferation and bone development in wild-type but not in Stat17/7 bone cultures. Overproduction of FGF-2 in transgenic mice impairs growth of long bones, leading to dwar®sm (Con et al., 1995) , a phenotype that is suppressed by absence of Stat1 (unpublished data). Thus, FGF signaling is capable of inhibiting speci®cally the proliferation of chondrocytes, in spite of its growth promoting activity on other cell types. Moreover, this inhibition of proliferation requires Stat1, though the biochemical basis for this cell type selectivity remains unclear.
Stat5
Analysis of Stat5 is of particular interest because it has been implicated downstream of a variety of cytokines involved in hematopoietic cell growth. Moreover, it has been shown to become constitutively activated in a variety of tumors, particularly those of hematopoietic origin. However, the analysis of the role for Stat5 in vivo has been complicated by the existence of the two nearly-identical genes Stat5a and Stat5b closely linked on chromosome 11 (Copeland et al., 1995) . Due to the diculty in producing a double knockout, de®ciencies for Stat5a and Stat5b were ®rst examined individually. As expected from the original characterization of Stat5 as mammary gland factor (Wakao et al., 1994) , the phenotype of Stat5a-de®cient mice showed impaired mammary gland development and lactogenesis . Stat5a-de®cient mice developed normally and were indistinguishable from hemizygous and wildtype littermates in size, weight and fertility. However, mammary lobulalveolar outgrowth during pregnancy was curtailed, and females failed to lactate after parturition because of a failure of terminal dierentiation, suggesting that the presence of Stat5b was insucient to compensate for the loss of Stat5a. One potential explanation for the lack of redundancy could be the signi®cant reduction in Stat5b protein levels observed in the absence of Stat5a. While the aects of Stat5a de®ciency on mammary gland development were striking, it was observed that expression of only some milk protein genes was aected. Whereas the promoters of many genes for milk proteins have been shown to depend on Stat binding sites for prolactin-induced expression, only production of whey acidic protein was severely impaired in the absence of Stat5a. Presumably, the reduced levels of Stat5b were capable of sustaining expression of other milk protein genes, providing evidence for discrete functions for these highly related transcription factors. Overall, the mammary develop phenotype of Stat5a-de®cient mice resembled that of prolactin receptor de®cient mice (Ormandy et al., 1997) , suggesting that Stat5a is indispensable for this aspect of prolactin function.
Disruption of Stat5b provided a very dierent picture, suggesting an indispensable role in growth hormone (GH) action (Udy et al., 1997) . Stat5b gene disruption led to a major loss of multiple, sexually dierentiated responses associated with the sexually dimorphic pattern of pituitary GH secretion. Malecharacteristic body growth rates and male-speci®c liver gene expression were decreased to wild-type female levels in Stat5b7/7 males, while female-predominant liver gene products were increased to a level intermediate between wild-type male and female levels. Pulsatile but not continuous GH exposure has been proposed to play a key role in regulating the sexual dimorphism of liver gene expression (Waxman et al., 1995) . Although the responses observed in Stat5b7/7 mice were similar to those observed in GH-de®cient Little mice, Stat5b7/7 mice were not GH-de®cient, suggesting that they may be only impaired in sensing GH pulses. Indeed, dwar®sm, elevated plasma GH, low plasma insulin-like growth factor I, and development of obesity were observed in Stat5b7/7 mice, and these are all characteristics of Laron-type dwar®sm, a human GH-resistance disease generally associated with a defective GH receptor. The requirement of Stat5b to maintain sexual dimorphism of body growth rates and liver gene expression suggests that Stat5b may be the major, if not the sole, Stat protein that mediates the sexually dimorphic eects of GH pulses in liver and perhaps other target tissues.
One of the surprises from disruptions of either Stat5a or Stat5b was the apparently normal development of the hematopoietic system, in spite of the many studies showing Stat5 activation in response to such hematopoietic cytokines as erythropoietin, IL2, IL3, IL5, GM-CSF, IL7, and CSF-1. However, an impairment in peripheral T lymphocyte proliferation was observed in the absence of Stat5a (Nakajima et al., 1997) . This defect appeared to be due to the loss of induced and sustained expression of the IL2 receptor asubunit which is necessary for maintenance of high anity cell surface receptors. T cell proliferation in the absence of induced a-subunit expression could be overcome by increased IL2, demonstrating that the defect in proliferation was due to an indirect eect of Stat5a on receptor expression. Interestingly, this defect was re¯ected by reduced T cell proliferation in vivo in response to antigenic stimulation, underscoring the importance of a-subunit induction during an immune response. A similar defect in NK cell proliferation was also observed in the absence of Stat5a (Imada et al., 1998) . However, in this case the defect could not be recti®ed by high dose IL2 and likely re¯ects an additional role for Stat5a in NK cells.
The results described for the individual inactivation of Stat5a and Stat5b were surprising, given the high degree of homology of these two proteins, their similar patterns of expression, and their almost indistinguishable set of activating cytokines. In fact, it was suspected that simultaneous inactivation of both genes would be required to produce a profound phenotype of Stat5 de®ciency. However, production of a Stat5a/b doubly-de®cient mouse strain was also a surprise. The genes for both Stat5a and Stat5b were individually disrupted in a single ES cell clone and used to produce mutant mice (Teglund et al., 1998) . Again, it was possible to derive viable, homozygous-null mice, and hematopoiesis in these animals was largely intact. Moreover, mice with individual Stat5a or Stat5b mutations displayed phenotypes that were somewhat discordant from the results reported previously from other labs, possibly due to dierences in the strain backgrounds used or the exact mutation constructed. Nonetheless, the phenotypes of these mice demonstrated an essential though often redundant role for the two Stat5 proteins in a spectrum of physiological responses associated with growth hormone and prolactin signaling; and yet, the responses to most Stat5-activating cytokines, including erythropoietin, were largely unaected, except possibly during fetal development (Socolovsky et al., 1999) . Impaired peripheral T lymphocyte proliferation was also observed in Stat5a,b7/7 mice, but this phenotype was ascribed to fundamental defects in cell cycle entry rather than to decreased IL2 receptor expression (Moriggl et al., 1999) . While lymphopoiesis was normal, T cells from Stat5 doubly-de®cient mice were profoundly impaired in proliferation and failed to undergo cell cycle progression or to express some of the genes controlling cell cycle progression. In addition, the mice lacked NK cells, developed splenomegaly, and their T cells displayed an activated phenotype. These phenotypes are strikingly similar to those seen in IL-2 or IL-2 receptor b chain-de®cient mice (Sadlack et al., 1993; Suzuki et al., 1995) . These phenotypes are not seen in mice lacking Stat5a or Stat5b alone, even though similar T cell and NK cell de®ciencies were observed in Stat5a7/7 mice developed independently (Nakajima et al., 1997) . The reasons underlying the discrepancies between Stat5-mutant mice developed in dierent labs are currently unclear.
Stat5 and cancer
Normal hematopoiesis in Stat5-de®cient mice was somewhat surprising, and suggested that Stat5 plays only a limited role in cell proliferation. However, impaired mammary gland expansion and defective T cell proliferation show that Stat5 nonetheless possesses the ability to regulate cell growth. Given the wide variety of malignancies that show constitutively active Stat5; it was therefore of interest to examine experimental carcinogenesis in the absence of these proteins. Transformation by tyrosine kinase fusion genes associated with human leukemia has been persistently linked to activation of Stat5. For instance, BCR/ABL expression due to Philadelphia chromosome translocation leads to Stat1 and Stat5 activation in chronic myelogenous leukemia (Carlesso et al., 1996; Chai et al., 1997; Ilaria and Van Etten, 1996; Shuai et al., 1996) , and fusion of the JAK2 protein to the ets protein TEL causes Stat activation and myeloproliferative disease (Ho et al., 1999; Lacronique et al., 1997; Schwaller et al., 1998) . Stat5 is also activated by the TEL/PDGFbR, TEL/ABL and HIP1/PDGFbR oncogenic fusion proteins (Okuda et al., 1996; Ross and Gilliland, 1999; Sternberg et al., 1999) . Experi-mentally, a constitutively active Stat5a mutant is capable of transforming hematopoietic cell lines to growth-factor independence in vitro (Onishi et al., 1998) , and leukemia induced by v-Abl has been associated with Stat protein phosphorylation (Danial et al., 1995 (Danial et al., , 1998 .
To address the requirements for Stat proteins in these leukemias, mice were transplanted with bone marrow transduced with a retrovirus expressing v-Abl, TEL/JAK2 or BCR/ABL. Mice transplanted with transduced cells derived from wild-type mice developed a rapidly fatal myeloproliferative and lymphoproliferative disease. To test whether Stat1 and/or Stat5 activation were necessary for disease induction, bone marrow cells from mutant mice de®cient in either Stat1 or Stat5a/b were similarly transduced and transplanted into recipients. Interestingly, wild-type Stat1-de®cient, and Stat5-de®cient hematopoietic progenitors all caused rapidly fatal myeloproliferative disease in recipient mice when transduced with the BCR/ABL fusion gene, as did Stat5-de®cient cells infected with vAbl, demonstrating that these phenotypes do not require activation of either Stat1 or Stat5 (unpublished data and J Ihle, personal communication). In contrast, while Stat1-de®cient cells transduced with the TEL/ JAK2 fusion virus were capable of conferring a myeloproliferative phenotype in recipient mice, animals transplanted with Stat5a/b de®cient cells transduced with the TEL/JAK2 fusion gene remained disease free. These data indicate that activation of Stat5 is required for the myelo-and lymphoproliferative disease induced by TEL/JAK2. In control experiments, Stat5a/bde®cient bone marrow transduced with a bicistronic retrovirus encoding both TEL/JAK2 and Stat5a was fully capable of producing disease in a Stat5-de®cient background. These data demonstrate that Stat5 is necessary for TEL/JAK2 induced disease. In addition, mice reconstituted with bone marrow infected with a retrovirus expressing the constitutively active Stat5a mutant also developed a rapidly fatal myeloproliferative syndrome, indicating that activation of Stat5a is also sucient to cause hematologic disease.
One transcriptional target gene for Stat5 is oncostatin M (OSM), a growth-promoting cytokine for myeloid cells. To test the possible involvement of Stat5-induced OSM production in TEL/JAK2 disease, bone marrow was transduced with a retrovirus programming ectopic production of OSM. Some aspects of the TEL/JAK2 disease phenotype could be recapitulated by expression of this single Stat5 target gene alone, including leukocytosis, extramedullary hematopoiesis, and bone marrow ®brosis. In contrast, no disease was induced by expression of another Stat5 target gene, Bcl-X. These data demonstrate that activation of Stat5 is both necessary and sucient for transformation by TEL/JAK2, and that Stat5 activation, leading to induction of the single downstream target gene OSM, is sucient to induce a lethal myeloproliferative disease.
Conclusions
Stat1 and Stat5 are both involved in a variety of growth regulatory processes. However, in spite of being constitutively activated in a variety of malignancies, they are not always required for this process. In fact, the evidence would suggest that activated Stat1 most often serves a growth-inhibitory function and therefore its activation in cancer may represent the remnants of a growth control pathway that has been overcome by the dominant growth-promoting activity of an activated oncogene. Genetic studies in mice revealed that loss of Stat1 can contribute to oncogenesis both by leading to deregulation of the cell cycle and by impairing the ability of tumors to be recognized and rejected by the immune system. In contrast, no role for activated Stat1 in promoting cell growth or increasing the malignancy of tumors has been documented, and Stat1-de®cient cells are susceptible to malignant transformation by a variety of oncogenes.
A dierent picture has emerged from studies of cell growth and transformation in Stat5-de®cient mice. Stat5 contributes to the normal growth of T lymphocytes, and therefore may play a role in lymphomagenesis. In spite of the apparent lack of a role in normal myelopoiesis, Stat5 can nonetheless contribute to myeloproliferative disease. This is most dramatically illustrated by TEL/JAK2 induced disease, in which activation of Stat5 is both necessary and sucient for disease induction and where induction of a single Stat5 target gene can signi®cantly aect cell proliferation. However, in other situations, most signi®cantly in diseases caused by BCR/ABL or vAbl, Stat5 activation appears not to play a necessary role, in spite of its activation being a hallmark of these diseases. In this situation, activation of Stat5 may potentiate the malignant phenotype but it is not absolutely required, although its role in these malignancies may be masked by other transforming events that are themselves sucient to cause disease.
